BAY-293 is primarily used in research settings as a potent and selective inhibitor of the KRAS G12C mutant protein, which is implicated in various cancers, particularly non-small cell lung cancer. Its main application lies in targeted cancer therapy development, where it helps block the signaling pathways that promote tumor growth. Due to its high specificity, BAY-293 is valuable in studying the biological effects of KRAS inhibition and serves as a tool compound in preclinical studies to evaluate therapeutic efficacy, resistance mechanisms, and potential combination treatments with other oncology drugs.